my pleasure
Some quick take aways - I think the ROW will not be as significant 'block buster' type deal as some expect.
To me I see it as a bonus but the USA is really where the money is made. I posted awhile back that a discussion I had with a high level industry contact suggested we'd get revenue from Europe and Japan but less than USA and not much from other ROW regions (relatively speaking).
Apart from the bonus, I think ROW will be more about getting the drug to kids who need it.
He seemed very bullish about the Phelan trial. Shame he's not there to be 'cornered' by attendees.
Some very good questions from the floor.
Neuren AGM 30th May, page-33
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |